Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

286
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
286
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Hematopoiesis01:21

Hematopoiesis

5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

COVID-19 Vaccine Reactogenicity Marks an Innate Inflammatory Response Associated With HLA Variation and Enhanced Protection.

Research square·2026
Same author

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Phenotype List String Grammar for Enhanced Protein and Antigen Reporting in the Immunogenetic Context.

HLA·2026
Same author

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Blood advances·2026
Same author

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Blood advances·2026
Same author

HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Bone marrow transplantation·2026

相关实验视频

Updated: Jun 8, 2025

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.2K

新的评分系统,用于排名血造干细胞移植的血造干细胞移植.

Lee Ann Baxter-Lowe1, Tao Wang2,3, Michelle Kuxhausen4

  • 1University of Southern California and Children's Hospital Los Angeles, Los Angeles, California, USA.

Clinical transplantation
|November 8, 2024
PubMed
概括

在血造干细胞移植 (HSCT) 中的人类白细胞抗原 (HLA) 不匹配的新评分系统没有显著预测结果. 然而,没有结差异的HLA不匹配 (分数=0) 可能表明更好的移植相关死亡率,扩大了允许的供体选择.

关键词:
在HLA不匹配的情况下.这就是HSCT的特点.评分系统 评分系统没有关系的捐赠者.

更多相关视频

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K
Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.1K

相关实验视频

Last Updated: Jun 8, 2025

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.2K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K
Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.1K

科学领域:

  • 免疫遗传学 免疫遗传学
  • 移植免疫学 移植免疫学
  • 血液学 血液学 血液学

背景情况:

  • 造血干细胞移植 (HSCT) 依赖于人类白细胞抗原 (HLA) 匹配,以获得最佳的结果.
  • 由于缺乏普遍接受的指导方针来排名7/8 HLA匹配的非相关捐赠者,当 HLA匹配的捐赠者无法获得时,这就带来了挑战.
  • 研究了一种新的评分系统,以对与无关的捐赠者HSCT中的HLA不匹配进行排名.

研究的目的:

  • 研究一种新的评分系统,用于在7/8 HLA匹配的无关捐赠体HSCT中排名单个HLA I类不匹配.
  • 评估这种评分系统与整体存活率和急性移植对宿主疾病 (GVHD) 的关联.

主要方法:

  • 高分辨率的HLA类型识别用于识别HLA抗原识别域中的氨基酸不匹配.
  • 基于影响结的物理化学性质,T细胞受体对接以及HLA结构/功能的不匹配的评分.
  • 对2319名白血病/骨髓质疏松症候群患者的队列进行分析,这些患者接受了第一个无关联的供体HSCT.

主要成果:

  • 新的评分系统与移植结果 (整体存活率,急性GVHD) 没有显著的相关性.
  • 分数为0 (没有结变化) 与较低的移植相关死亡率 (TRM) 相关 (p=0.019).
  • 与分数 = 0 的HLA不匹配包括HLA-C*03:03/03:04和其他特定不匹配,此前被认为是允许的.

结论:

  • 没有改变结的HLA不匹配 (分数 = 0) 可能代表允许的不匹配,可能会扩大捐赠池.
  • 需要进一步的研究来验证这些发现,并探索用于HLA不匹配供体选择的替代评分系统.